Henrik Almroth

846 total citations
19 papers, 342 citations indexed

About

Henrik Almroth is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Economics and Econometrics. According to data from OpenAlex, Henrik Almroth has authored 19 papers receiving a total of 342 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Cardiology and Cardiovascular Medicine, 5 papers in Surgery and 5 papers in Economics and Econometrics. Recurrent topics in Henrik Almroth's work include Atrial Fibrillation Management and Outcomes (15 papers), Cardiac Arrhythmias and Treatments (11 papers) and Cardiac electrophysiology and arrhythmias (6 papers). Henrik Almroth is often cited by papers focused on Atrial Fibrillation Management and Outcomes (15 papers), Cardiac Arrhythmias and Treatments (11 papers) and Cardiac electrophysiology and arrhythmias (6 papers). Henrik Almroth collaborates with scholars based in Sweden, Greece and Germany. Henrik Almroth's co-authors include Scott Montgomery, Katja Fall, Ruzan Udumyan, Anders Englund, Cecilia Bergh, Mårten Rosenqvist, Fang Fang, Anders Ekbom, Karin E. Smedby and Unnur Valdimarsdóttir and has published in prestigious journals such as Cancer Research, European Heart Journal and Heart.

In The Last Decade

Henrik Almroth

19 papers receiving 318 citations

Peers

Henrik Almroth
Daniel S. Atherton United States
David Trueman United States
Eunice Jung United States
Scott Lancaster United States
Şule Arslan Türkiye
Monica Moz Italy
Nicol Kurstjens Australia
S. Simon United States
Nicolas Christodoulou Cyprus
Redoy Ranjan Bangladesh
Daniel S. Atherton United States
Henrik Almroth
Citations per year, relative to Henrik Almroth Henrik Almroth (= 1×) peers Daniel S. Atherton

Countries citing papers authored by Henrik Almroth

Since Specialization
Citations

This map shows the geographic impact of Henrik Almroth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Henrik Almroth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Henrik Almroth more than expected).

Fields of papers citing papers by Henrik Almroth

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Henrik Almroth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Henrik Almroth. The network helps show where Henrik Almroth may publish in the future.

Co-authorship network of co-authors of Henrik Almroth

This figure shows the co-authorship network connecting the top 25 collaborators of Henrik Almroth. A scholar is included among the top collaborators of Henrik Almroth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Henrik Almroth. Henrik Almroth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Jensen‐Urstad, Mats, Emmanouil Charitakis, Finn Åkerström, et al.. (2025). Individually designed ablation of low-voltage areas in persistent atrial fibrillation—a randomized controlled trial (IDEAL-AF): study design and rationale. European Heart Journal Open. 5(2). oeaf037–oeaf037. 2 indexed citations
2.
Almroth, Henrik, Lars Karlsson, Carl‐Johan Carlhäll, & Emmanouil Charitakis. (2023). Haemodynamic changes after atrial fibrillation initiation in patients eligible for catheter ablation: a randomized controlled study. European Heart Journal Open. 3(6). oead112–oead112. 2 indexed citations
3.
Charitakis, Emmanouil, Elena Dragioti, Stylianos Tzeis, et al.. (2022). Predictors of recurrence after catheter ablation and electrical cardioversion of atrial fibrillation: an umbrella review of meta-analyses. EP Europace. 25(1). 40–48. 18 indexed citations
4.
Charitakis, Emmanouil, Silvia Metelli, Lars Karlsson, et al.. (2022). Comparing efficacy and safety in catheter ablation strategies for atrial fibrillation: a network meta-analysis. BMC Medicine. 20(1). 193–193. 10 indexed citations
5.
Charitakis, Emmanouil, Silvia Metelli, Lars Karlsson, et al.. (2022). Comparing Efficacy and Safety in Catheter Ablation Strategies for Paroxysmal Atrial Fibrillation: A Network Meta-Analysis of Randomized Controlled Trials. Diagnostics. 12(2). 433–433. 4 indexed citations
6.
Walfridsson, Ulla, Anders Jönsson, Lars Karlsson, et al.. (2021). Symptoms and health‐related quality of life 5 years after catheter ablation of atrial fibrillation. Clinical Cardiology. 45(1). 42–50. 10 indexed citations
7.
Charitakis, Emmanouil, Lars Karlsson, Konstantinos D. Rizas, et al.. (2020). Comparing efficacy and safety in catheter ablation strategies for atrial fibrillation: protocol of a network meta-analysis of randomised controlled trials. BMJ Open. 10(11). e041819–e041819. 2 indexed citations
8.
Almroth, Henrik, Lars Karlsson, Anders Jönsson, et al.. (2020). [Evaluation and treatment of PVC's].. PubMed. 117. 1 indexed citations
9.
Almroth, Henrik, et al.. (2020). Fulminant myocarditis in a COVID-19 positive patient treated with mechanical circulatory support – a case report. European Heart Journal - Case Reports. 5(2). ytaa523–ytaa523. 17 indexed citations
10.
Walfridsson, Ulla, Peter S. Hansen, Emmanouil Charitakis, et al.. (2019). Gender and age differences in symptoms and health‐related quality of life in patients with atrial fibrillation referred for catheter ablation. Pacing and Clinical Electrophysiology. 42(11). 1431–1439. 12 indexed citations
11.
Udumyan, Ruzan, Scott Montgomery, Fang Fang, et al.. (2017). Beta-Blocker Drug Use and Survival among Patients with Pancreatic Adenocarcinoma. Cancer Research. 77(13). 3700–3707. 76 indexed citations
12.
Fengsrud, Espen, Anders Wickbom, Henrik Almroth, Anders Englund, & Anders Ahlsson. (2016). Total endoscopic ablation of patients with long-standing persistent atrial fibrillation: a randomized controlled study. Interactive Cardiovascular and Thoracic Surgery. 23(2). 292–298. 6 indexed citations
13.
Bergh, Cecilia, Ruzan Udumyan, Katja Fall, Henrik Almroth, & Scott Montgomery. (2015). Stress resilience and physical fitness in adolescence and risk of coronary heart disease in middle age. Heart. 101(8). 623–629. 54 indexed citations
14.
Höglund, Niklas, Jonas Andersson, Henrik Almroth, et al.. (2012). The predictive value of C-reactive protein on recurrence of atrial fibrillation after cardioversion with or without treatment with atorvastatin. International Journal of Cardiology. 167(5). 2088–2091. 4 indexed citations
15.
Almroth, Henrik. (2012). Atrial fibrillation : inflammatory and pharmacological studies. KTH Publication Database DiVA (KTH Royal Institute of Technology). 17 indexed citations
16.
Andersson, Jonas, Henrik Almroth, Niklas Höglund, et al.. (2011). Markers of fibrinolysis as predictors for maintenance of sinus rhythm after electrical cardioversion. Thrombosis Research. 127(3). 189–192. 2 indexed citations
17.
Almroth, Henrik, Tommy Andersson, Espen Fengsrud, et al.. (2011). The safety of flecainide treatment of atrial fibrillation: long-term incidence of sudden cardiac death and proarrhythmic events. Journal of Internal Medicine. 270(3). 281–290. 27 indexed citations
18.
Jøns, Christian, Peter S. Hansen, Arne Johannessen, et al.. (2009). The Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Paroxysmal Atrial Fibrillation (MANTRA-PAF) Trial: clinical rationale, study design, and implementation. EP Europace. 11(7). 917–923. 30 indexed citations
19.
Almroth, Henrik, Niklas Höglund, Kurt Boman, et al.. (2008). Atorvastatin and persistent atrial fibrillation following cardioversion: a randomized placebo-controlled multicentre study. European Heart Journal. 30(7). 827–833. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daniel S. Atherton Breakdown of academic impact, for papers by David Trueman Breakdown of academic impact, for papers by Eunice Jung Breakdown of academic impact, for papers by Scott Lancaster Breakdown of academic impact, for papers by Şule Arslan Breakdown of academic impact, for papers by Monica Moz Breakdown of academic impact, for papers by Nicol Kurstjens Breakdown of academic impact, for papers by S. Simon Breakdown of academic impact, for papers by Nicolas Christodoulou Breakdown of academic impact, for papers by Redoy Ranjan
Rankless by CCL
2026